Remix Therapeutics has raised $81 million in a round led by Foresite Capital, with participation from Atlas Ventures and The Column Group. The Cambridge, Mass.-based biotech startup is developing small-molecule therapies that work to treat cancer and other diseases by reprogramming RNA processing.